Vanda Pharmaceuticals的Fanapt®（伊潘立酮）获得美国食品药品监督管理局批准用于急性治疗双相情感障碍-动脉橙

Vanda Pharmaceuticals的Fanapt®（伊潘立酮）获得美国食品药品监督管理局批准用于急性治疗双相情感障碍

2024-04-02 BioSpace 等4家媒体报道 FDA动态





Vanda Pharmaceuticals宣布，FDA已批准Fanapt®用于急性治疗双相I型障碍成人的躁狂或混合发作。Fanapt®是一种非典型抗精神病药物，自2009年以来一直用于治疗精神分裂症。这项批准为躁郁症I提供了一种新的治疗选择，这种严重的疾病影响了2.8%的美国成年人。双相I型障碍涉及情绪升高和抑郁的交替时期，躁狂症是一个关键的诊断特征。（摘要由动脉网AI生成）

2024-04-02 Vanda Pharmaceuticals' Fanapt® (iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I Disorder

BioSpace
2024-04-02 Vanda's Fanapt Gets FDA Approval For Acute Treatment Of Bipolar I Disorder; Stock Up In After-hours

RTTNews
2024-04-02 Vanda Pharmaceuticals' Fanapt (iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I Disorder

Drugs
2024-04-02 Vanda Pharmaceuticals' Fanapt® (iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I Disorder

PR Newswire